Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) cultivated its 70th variety of psilocybin-containing mushrooms at its 3,500 square foot GMPcompliant facility in Metro Vancouver. Filament also announced the successful development of standardized, pharmaceutical grade ayahuasca extract, designed for oral administration by capsule or tablet.

The drug product was manufactured using Filament’s proprietary processing and standardization technology. Filament’s library includes 42 varieties of Psilocybe cubensis in addition to further varieties belonging to other psilocybinproducing species. The Company’s research and development team is conducting ongoing cultivation, screening, and analysis to determine the highest potency and efficacy of different cultivars, as well as optimal cultivation techniques and growing conditions to maximize yields.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.